Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan - PubMed (original) (raw)
Clinical Trial
doi: 10.1016/j.bbmt.2006.11.024. Epub 2007 Feb 8.
Sergio Giralt, Rima Saliba, Chitra Hosing, Uday Popat, Issa Khouri, Daniel Couriel, Muzaffar Qazilbash, Paolo Anderlini, Partow Kebriaei, Shubhra Ghosh, Antonio Carrasco-Yalan, Ernesto de Meis, Athanasios Anagnostopoulos, Michele Donato, Richard E Champlin, Marcos de Lima
Affiliations
- PMID: 17382251
- PMCID: PMC4080636
- DOI: 10.1016/j.bbmt.2006.11.024
Clinical Trial
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan
Betul Oran et al. Biol Blood Marrow Transplant. 2007 Apr.
Abstract
Reduced-intensity conditioning has extended the use of allogeneic hematopoietic stem cell transplantation (HSCT) to patients otherwise not eligible for this treatment due to older age or frailty. One hundred twelve acute myelogenous leukemia/myelodysplastic syndromes patients received fludarabine and melphalan (FM) conditioning with allogeneic HSCT. Most patients (73%) were not in remission. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and mini-methotrexate. Median age was 55 years (range, 22-74). Donors were related (53%) and unrelated (47%). Median follow-up of surviving patients (n = 43) was 29.4 months (range, 13.1-87.7). The complete remission (CR) rate was 82%. Estimates of 2-year survival were 66%, 40%, and 23% for patients in CR, with active disease without and with circulating blasts at HSCT, respectively. In multivariate analysis, survival was negatively influenced by active disease at HSCT and development of grade II-IV acute GVHD. Presence of circulating blasts at HSCT negatively influenced freedom from disease progression. Incidence of nonrelapse mortality (NRM) was significantly higher for patients with active disease, but was not influenced by patient age. Patients in CR had a day-100 and 2-year NRM of 0% and 20%, respectively. Use of unrelated donors increased the risk of NRM only among patients with active disease. FM and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort.
Figures
Figure 1
(A) Patients in complete remission at transplantation: survival, cumulative incidence of disease relapse, and nonrelapse mortality, showed by melphalan dose in the conditioning regimen (solid line, fludarabine [F] and melphalan [M] 100 mg/m2; tight dashed line, FM180 mg/m2; spaced dashed line, FM140 mg/m2). Patients receiving FM100 in complete remission were older than those treated with FM140 or FM180 (59 versus 43 years, P = .002). Most patients in the FM100 subgroup were in first remission, while recipients of FM140 or FM180 were mostly in second remission. Differences in outcomes were not statistically significant. (B) Patients with active disease at transplantation: survival, cumulative incidence of disease relapse, and nonrelapse mortality showed by melphalan dose (tight dashed line, FM180 mg/m2; spaced dashed line, FM 140 mg/m2). Differences in outcomes were not statistically significant.
Figure 2
Cumulative incidence of disease progression by disease status at transplantation.
Figure 3
Overall survival by disease status at transplantation. Kaplan-Meier estimates of overall survival of all patients, as a function of disease status at transplantation. Estimates of 2-year overall survival were 66% for those in remission, 40% for patients with active disease without circulating blasts, and 23% for those with circulating blasts. P = .0007 for the overall comparison. Compared to patients in remission, patients with active disease at transplantation had worse survival (P = .02, for the comparison with patients with circulating blasts, and P = .06, for patients without circulating blasts). Among patients with active disease, presence of peripheral blood blasts was associated with worse survival (P = .06).
Figure 4
Cumulative incidence of nonrelapse mortality was higher for patients transplanted with active disease.
Similar articles
- Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G. Saure C, et al. Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29. Biol Blood Marrow Transplant. 2012. PMID: 21963618 Clinical Trial. - Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH. Slack JL, et al. Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7. Biol Blood Marrow Transplant. 2013. PMID: 23664940 - Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group. Kröger N, et al. Ann Hematol. 2003 Jun;82(6):336-42. doi: 10.1007/s00277-003-0654-9. Epub 2003 May 1. Ann Hematol. 2003. PMID: 12728337 Clinical Trial. - Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D, Martino R. Valcárcel D, et al. Curr Opin Oncol. 2007 Nov;19(6):660-6. doi: 10.1097/CCO.0b013e3282f0e188. Curr Opin Oncol. 2007. PMID: 17906468 Review. - Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.
Zhang ZH, Lian XY, Yao DM, He PF, Ma JC, Xu ZJ, Guo H, Zhang W, Lin J, Qian J. Zhang ZH, et al. J Cancer Res Clin Oncol. 2017 Sep;143(9):1853-1864. doi: 10.1007/s00432-017-2429-z. Epub 2017 May 3. J Cancer Res Clin Oncol. 2017. PMID: 28470473 Review.
Cited by
- FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia-Even in the Era of New Treatment Modalities Still a Significant Player.
Anžej Doma S, Sever M, Jakoš G, Podgornik H. Anžej Doma S, et al. J Clin Med. 2024 Mar 22;13(7):1842. doi: 10.3390/jcm13071842. J Clin Med. 2024. PMID: 38610607 Free PMC article. - Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.
Esquirol A, Cadenas IG, Novelli S, Garrido A, Caballero AC, Oñate G, Lopez J, Redondo S, Argüello M, Saavedra S, Moreno C, Briones J, Sierra J, Martino R. Esquirol A, et al. Ann Hematol. 2024 Jan;103(1):321-334. doi: 10.1007/s00277-023-05530-w. Epub 2023 Nov 16. Ann Hematol. 2024. PMID: 37971549 - Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.
Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Short NJ, et al. Blood Adv. 2023 Jul 25;7(14):3573-3581. doi: 10.1182/bloodadvances.2022009632. Blood Adv. 2023. PMID: 37104058 Free PMC article. - Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes.
Duda K, Wieczorkiewicz-Kabut A, Spałek A, Koclęga A, Kopińska AJ, Woźniczka K, Helbig G. Duda K, et al. Indian J Hematol Blood Transfus. 2022 Oct;38(4):680-690. doi: 10.1007/s12288-021-01508-8. Epub 2021 Dec 10. Indian J Hematol Blood Transfus. 2022. PMID: 36258723 Free PMC article. - Decision Analysis of Transplantation for Patients with Myelodysplasia: "Who Should We Transplant Today?".
Arslan S, Nakamura R. Arslan S, et al. Curr Hematol Malig Rep. 2020 Aug;15(4):305-315. doi: 10.1007/s11899-020-00573-6. Curr Hematol Malig Rep. 2020. PMID: 32222884 Free PMC article. Review.
References
- Litzow MR, Perez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol. 2002;119:1115–1124. - PubMed
- de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood. 2001;98:2326–2331. - PubMed
- Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479–485. - PubMed
- Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302–1311. - PubMed
- Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992;79:473–476. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical